MENU
+Compare
ARDX
Stock ticker: NASDAQ
AS OF
Dec 18, 11:38 AM (EDT)
Price
$4.41
Change
-$0.25 (-5.36%)
Capitalization
1.1B

ARDX Ardelyx Forecast, Technical & Fundamental Analysis

a developer of therapeutic drugs that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases

Industry Biotechnology
ARDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
a Summary for ARDX with price predictions
Dec 17, 2024

ARDX in upward trend: price expected to rise as it breaks its lower Bollinger Band on December 17, 2024

ARDX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 38 cases where ARDX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ARDX's RSI Oscillator exited the oversold zone, of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ARDX advanced for three days, in of 262 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 11, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on ARDX as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ARDX turned negative on December 17, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARDX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ARDX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.974) is normal, around the industry mean (14.664). P/E Ratio (0.000) is within average values for comparable stocks, (87.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.783). ARDX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (4.329) is also within normal values, averaging (260.687).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ARDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ARDX is expected to report earnings to rise ∞% to 0 cents per share on March 05

Ardelyx ARDX Stock Earnings Reports
Q4'24
Est.
$0.00
Q3'24
Beat
by $0.05
Q2'24
Beat
by $0.04
Q1'24
Beat
by $0.03
Q4'23
Missed
by $0.03
The last earnings report on October 31 showed earnings per share of 0 cents, beating the estimate of -5 cents. With 1.55M shares outstanding, the current market capitalization sits at 1.10B.
A.I. Advisor
published General Information

General Information

a developer of therapeutic drugs that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
400 Fifth Avenue
Phone
+1 510 745-1700
Employees
267
Web
https://www.ardelyx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IRFRX8.060.01
+0.12%
Cohen & Steers International Realty R
ECEAX34.24N/A
N/A
Eaton Vance Tax-Managed Eq Aset Allc C
MERFX17.57N/A
N/A
The Merger Fund A
ARDEX6.28N/A
N/A
AMG River Road Dividend All Cap Value N
CCCRX36.02-0.09
-0.25%
Columbia Contrarian Core R

ARDX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ARDX has been loosely correlated with VCYT. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ARDX jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARDX
1D Price
Change %
ARDX100%
-13.54%
VCYT - ARDX
45%
Loosely correlated
-2.52%
HRTX - ARDX
41%
Loosely correlated
-1.79%
PTGX - ARDX
40%
Loosely correlated
-1.86%
XENE - ARDX
40%
Loosely correlated
-0.07%
NKTX - ARDX
39%
Loosely correlated
-1.73%
More